Information Provided By: 
Fly News Breaks for March 17, 2017
AMGN, MDCO
Mar 17, 2017 | 10:45 EDT
Leerink analyst Joseph Schwartz says Amgen's (AMGN) cholesterol lowering data this morning is less positive than expectations, in part due to management's bullishness ahead of the news. The analyst sees a "less than perfect read-through" to The Medicines Co. (MDCO), however, since the company is likely to study inclisiran in patients with more elevated cholesterol going forward. He reiterates an Outperform rating on Medicines shares. The stock is morning trading is down 21% to $41.38.
News For MDCO;AMGN From the Last 2 Days
There are no results for your query MDCO;AMGN
